Chemotherapy before surgery for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before surgery to shrink the tumor in people with a specific type of pancreatic cancer. The goal is to make surgery more effective and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with a type of pancreatic cancer called pancreatic ductal adenocarcinoma, which is considered borderline resectable (meaning it may be removable with surgery but is close to blood vessels).
- You must not have had chemotherapy or radiation therapy for this cancer before.
- Your overall health must be good enough to undergo treatment, including having adequate blood cell counts and liver and kidney function.
- If you are able to become pregnant, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs given before surgery for pancreatic cancer that is removable or borderline removable. The goal is to shrink the tumor to make surgery more successful.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
This study uses MRI scans to see how well chemotherapy and radiation work in people with borderline resectable pancreatic cancer – a type where surgery might be possible but is risky. The goal is to find the best way to measure tumor response so doctors can make better treatment decisions.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.